HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity

Table 1 Individual’s data summary

Individual	Geometric mean IC₅₀titer^a	Number of viruses neutralized^b	Date of SC^c	Months from SC to CVI^d	CD4 count at SP^e	Viral load (log) at SP^f	Env sequences obtained^g	Neutralization assay performed^h	SH analysis performedⁱ
ACH19829	297	6	26-jan-86	10.5	440	3.9	gp160	+	+
ACH18969	275	5	29-Oct-87	1.8	520	4.3	gp160	+	+
ACH19308	231	5	14-jul-91	3.3	380	4.4	gp160	+	+
ACH18814	230	6	27-jul-87	3.2	500	5.1	gp160	+	+
ACH18818	205	4	26-jan-86	8.2	510	5.4	gp160	+	+
ACH19885	180	5	28-dec-94	2.9	580	3.3	gp160	+	+
ACH11668	169	5	28-jun-86	7.9	380	4.5	gp160	+	+
ACH19463	164	5	14-jul-86	2.1	350	4.8	gp160	+	+
ACH19507	140	6	23-apr-88	7.9	400	5.0	gp160	+	+
ACH19474	126	5	27-jul-87	12.7	410	3.0	gp160	+	+
ACH19999	111	4	26-aug-85	4.3	1060	4.6	gp160	+	+
ACH19793	93	4	28-jun-86	12.3	1000	4.5	gp160	+	+
ACH19588	91	4	20-nov-85	13.8	600	5.3	gp160	-	-
ACH19566	78	5	11-Mar-85	13.2	610	3.5	C1-V5	-	-
ACH19768	64	5	6-apr-86	2.2	370	3.7	gp160	-	-
ACH18860	64	2	25-aug-86	2.6	550	4.9	C1-V5	-	-
ACH18839	64	3	17-Oct-86	3.3	330	3.8	C1-V5	-	-
ACH19542	45	3	23-jun-85	4.5	310	3.9	gp160	-	-
ACH18766	43	1	15-jul-88	5.1	760	4.3	gp160	-	-
ACH19861	43	3	24-feb-89	3.0	470	4.3	gp160	+	+
ACH19453	39	3	23-dec-85	7.0	810	3.0	gp160	-	-
ACH18829	38	3	2-feb-87	4.0	770	2.6	C1-V5	-	-
ACH19792	34	2	8-nov-85	6.9	450	4.9	gp160	+	+
ACH19961	31	0	14-sep-87	2.4	530	4.5	gp160	+	+
ACH19329	31	1	28-dec-94	4.3	780	3.9	gp160	+	+
ACH19974	29	2	26-jan-86	8.8	550	3.5	gp160	+	+
ACH19489	29	0	30-sep-85	7.4	550	3.1	gp160	+	+
ACH18887	29	1	7-dec-89	8.8	670	4.6	gp160	+	+
ACH19342	28	2	14-jul-86	3.0	700	3.9	C1-V5	-	-
ACH19576	23	1	2-feb-88	7.0	500	4.5	gp160	+	+
ACH18880	20	0	28-jun-86	10.4	860	4.8	gp160	+	+

^aNeutralization titers are expressed as the geometric mean of the reciprocal plasma dilution that inhibited virus infection by 50% for the panel of 6 heterologous viruses.
^bThe number of viruses neutralized, at least 3-fold higher than the IC₅₀ of the same serum with MLV, from the panel of 6 heterologous viruses from different subtypes.
^cDate of seroconversion (SC).
^dMonths post SC to time of clonal virus isolation (CVI).
^eCD4⁺ T-cell (CD4⁺) count at setpoint (SP).
^fLog viral load at setpoint (SP).
^gEnv fragment sequenced.
^hIndividuals from which viruses were used in the neutralization sensitivity assay with MAbs and polyclonal HIVIg pools are indicated with +.
^IIndividuals from which viral sequences were used in the Sequence Harmony model are indicated with +.

ISSN: 1742-4690